Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation
- PMID: 25721372
- DOI: 10.2340/00015555-2081
Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation
Abstract
There is a range of methotrexate dosing regimens for psoriasis. This review summarizes the evidence for test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and use of folic acid. A literature search for randomized controlled trials and guidelines was performed. Twenty-three randomized controlled trials (29 treatment groups) and 10 guidelines were included. Two treatment groups used a test-dose, 5 guidelines recommend it. The methotrexate start-dose in randomized controlled trials varied from 5 to 25 mg/week, most commonly being either 7.5 mg or 15 mg. Guidelines vary from 5 to 15 mg/week. Methotrexate was administered as a single dose or in a Weinstein schedule in 15 and 11 treatment-groups, respectively; both recommended equally in guidelines. A fixed dose (n = 18), predefined dose (n = 3), or dose adjusted on clinical improvement (n = 8) was used, the last also being recommended in guidelines. Ten treatment groups used folic acid; in 2 it was allowed, in 14 not mentioned, and in 3 no folic acid was used. Most guidelines recommend the use of folic acid. Authors' suggestions for methotrexate dosing are given.
Similar articles
-
The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom.Clin Exp Dermatol. 2000 Jun;25(4):265-8. doi: 10.1046/j.1365-2230.2000.00638.x. Clin Exp Dermatol. 2000. PMID: 10971481
-
Methotrexate in psoriasis: do we need to give a test dose?Actas Dermosifiliogr. 2012 Jan;103(1):1-4. doi: 10.1016/j.adengl.2011.05.006. Epub 2012 Mar 20. Actas Dermosifiliogr. 2012. PMID: 22440152 No abstract available.
-
Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review.Br J Dermatol. 2009 Mar;160(3):622-8. doi: 10.1111/j.1365-2133.2008.08876.x. Epub 2008 Oct 20. Br J Dermatol. 2009. PMID: 18945303 Review.
-
Folate supplementation during methotrexate therapy for patients with psoriasis.J Am Acad Dermatol. 2005 Oct;53(4):652-9. doi: 10.1016/j.jaad.2005.06.036. J Am Acad Dermatol. 2005. PMID: 16198787 Review.
-
[Correct use of methotrexate].Ned Tijdschr Geneeskd. 2009;153:A696. Ned Tijdschr Geneeskd. 2009. PMID: 19785852 Dutch.
Cited by
-
Deciphering Differential Behavior of Immune Responses as the Foundation for Precision Dosing in Allergen Immunotherapy.J Pers Med. 2023 Feb 13;13(2):324. doi: 10.3390/jpm13020324. J Pers Med. 2023. PMID: 36836557 Free PMC article. Review.
-
Challenge of Nail Psoriasis: An Update Review.Clin Rev Allergy Immunol. 2021 Dec;61(3):377-402. doi: 10.1007/s12016-021-08896-9. Epub 2021 Sep 3. Clin Rev Allergy Immunol. 2021. PMID: 34478047 Review.
-
Serum Metabolomic Profiling Reveals the Amelioration Effect of Methotrexate on Imiquimod-Induced Psoriasis in Mouse.Front Pharmacol. 2020 Nov 19;11:558629. doi: 10.3389/fphar.2020.558629. eCollection 2020. Front Pharmacol. 2020. PMID: 33364938 Free PMC article.
-
Acute Methotrexate Toxicity Due to Overdosing in Psoriasis: A Series of Seven Cases.Indian Dermatol Online J. 2019 Jan-Feb;10(1):64-68. doi: 10.4103/idoj.IDOJ_157_18. Indian Dermatol Online J. 2019. PMID: 30775303 Free PMC article.
-
Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1710-1727. doi: 10.1111/jdv.15019. Epub 2018 May 18. J Eur Acad Dermatol Venereol. 2018. PMID: 29705996 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical